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ABSTRACT
Hyperammonemia, a known cause of encephalopathy, is commonly seen in patients with liver disease. Non-cirrhotic hyperammonemia 
is an uncommon condition. Patients with uncontrolled diabetes can have elevated levels of ammonia. Diabetic ketoacidosis is a life-
threatening complication in diabetes. This is a case of a middle-aged male who presented in encephalopathy. He was found to have 
diabetic ketoacidosis with hyperammonemia. Encephalopathy as a result of hyperammonemia in diabetes mellitus is a rare scenario.
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Diabetes mellitus (DM) is a group of metabolic disorders that share the phenotype of hyperglycemia. Type 2 DM is a heterogeneous group of disorders characterized 
by insulin resistance, impaired insulin secretion and increased 
glucose production [1]. According to the WHO, the number of 
diabetic patients has increased from 108 million in 1980 to 422 
million in 2014; and the global prevalence of diabetes among 
adults above the age of 18 years has risen from 4.7% in 1980 to 
8.5% in 2014 [2]. India is regarded as the diabetic capital of the 
world, with the diabetic population expected to hit the mark of 
69.9 million by 2025 and 80 million by 2030 [3]. 
Diabetic ketoacidosis (DKA) is an acute severe life-
threatening complication of DM [1]. Diabetic patients tend 
to have altered protein metabolism due to abnormal glucose 
homeostasis resulting in hyperammonemia. Hyperammonemia is 
a metabolic disturbance where the levels of ammonia are elevated 
in the blood. This can be toxic to the brain. Encephalopathy 
due to hyperammonemia in a newly diagnosed diabetic patient 
presenting in DKA is a rare scenario.
CASE REPORT 
A 52-year-old male was brought to the Emergency department 
with 2 days history of delirium. He also complained of fatigue, 
polyuria, and polydipsia for the past 2 weeks and constipation for 
1 week. He was not a known case of any comorbid condition and 
was not on any regular medications. There was no history of any 
substance abuse. 
On examination, he was disoriented and dehydrated. His heart 
rate was 110/ minute (regular), blood pressure 90/60 mmHg, 
respiratory rate of 24/ minute with saturation 94% (room air). His 
systemic examinations were normal and there were no signs of 
meningeal irritation.
His complete blood counts, electrolytes, calcium, thyroid 
stimulating hormone (TSH), thyroid peroxidase antibody and 
liver functions were normal. Renal functions were deranged (urea 
92 mg/dL, creatinine 3.12 mg/dL). Random blood glucose was 
442 mg/dL and HbA1c 14.4%. Urine ketone was positive (5+) 
and arterial blood gas analysis showed acidosis (pH 7.21, pO2 
95mmHg, pCO2 29 mmHg, HCO3 11 mEq/L). Serum amylase 
was mildly elevated (110 U/L) but lipase was normal (90 U/L). 
Fasting lipid profile had high density lipoprotein (HDL) of 42 
mg/dL, low density lipoprotein (LDL) of 140 mg/dL, very low 
density lipoprotein (VLDL) of 32 mg/dL and triglycerides of 
255 mg/dL. Electrocardiogram (ECG) showed sinus tachycardia. 
Echocardiography, ultrasound abdomen and computed 
tomography (CT) scan of the brain were normal. Cerebrospinal 
fluid analysis (CSF) was also normal.
Ryle’s tube aspirate contained only food particles. He was 
managed with insulin and intravenous fluids as per the DKA 
treatment protocol. His vitals and renal parameters normalized. 
Blood glucose levels were maintained between 110 to 140 mg/dL. 
Though the patient became oriented, he continued to be drowsy. His 
plasma ammonium levels were elevated (97 µmol/L). He was given 
lactulose enema followed by lactulose syrup (15 ml) at night. Within 
2 days, his sensorium became normal following normalization of 
ammonia levels (30 µmol/L) and was discharged on premix insulin 
analogs. On review after 2 weeks, he was asymptomatic, with 
fasting and postprandial blood glucose levels of 118 mg/dL and 157 
mg/dL respectively, and plasma ammonia of 27 µmol/L.
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DISCUSSION 
In humans, ammonia is produced by the bacterial hydrolysis 
of intestinal urea and other nitrogenous compounds, the purine 
nucleotide cycle, the transamination of amino acid in skeletal 
muscle and other metabolic processes that take place in the liver 
and kidneys. Hyperammonemia can lead to neurological disorders 
when excess ammonia crosses the blood-brain barrier [4]. 
The primary cause for hyperammonemia is a congenital 
defect in enzymes of the urea cycle such as deficiencies of 
ornithine argininosuccinate lyase and transcarbamoylase. 
Secondary hyperammonemia is commonly seen in patients 
with liver disease leading to portosystemic encephalopathy. 
It can also occur in disorders like Reye’s syndrome, infection 
in a neurogenic bladder and ureterosigmoidostomy [5-7]. 
Drugs like cyanide, valproic acid, carbamazepine and iron, in 
toxic amounts, can disrupt mitochondrial pathways, thereby 
causing secondary hyperammonemia [8,9]. Chemotherapeutic 
agents like cyclophosphamide, 5-fluorouracil, cytarabine, 
vincristine, etoposide, L-asparaginase can cause non-cirrhotic 
hyperammonemia. Acute leukemia, multiple myeloma, and 
solid organ tumors can also have hyperammonemia as a rare 
complication [10-12]. Non-cirrhotic hyperammonemia has also 
been reported in cases of gastric bypass surgery [13].
Insulin increases the rate of protein synthesis and decreases 
the rate of protein degradation. Hence, insulin resistance or 
deficiency can lead to increased protein catabolism. Moreover, 
the slow transit constipation can facilitate increased absorption 
of ammonia into the mesenteric blood supply which is sufficient 
enough to overwhelm the hepatic excretory pathway [6,14]. 
In some patients, hyperinsulinemia has been associated with 
hyperammonemia. The increase in intracellular fat in the liver 
and skeletal muscles, which occurs in association with insulin 
resistance, can lead to a mitochondrial defect in substrate 
oxidation; thereby resulting in decreased mitochondrial density 
and mitochondrial copy number. This, in turn, can impair the urea 
cycle and cause hyperammonemia [15].
The diagnosis of non-cirrhotic hyperammonemia can be 
challenging, requiring a high level of suspicion. It should be 
considered when other causes like liver failure, azotemia, stroke, 
electrolyte imbalance, and thyroid disorders have been ruled out. A 
delay in recognition can lead to complications like encephalopathy. 
CONCLUSION 
Hyperammonemia is a common metabolic disorder in patients 
with liver disease but non-cirrhotic causes are uncommon. 
Hyperammonemia leading to encephalopathy is an uncommon 
complication in DM. This may be due to factors like high protein 
catabolism, slow transit of bowel contents, insulin resistance, 
infections, and mitochondrial dysfunction. 
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